Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition

已完结 10 由大三发布于 2026/11/7 22:01:16

DOI:10.1016/j.jaci.2026.08.022
作者：Jonathan Corren MD,?Larry Borish MD,?Christopher Brightling FMedSci, PhD,?Joseph K. Han MD,?Emma Guttman-Yassky MD, PhD,?Steven Ziegler PhD,?Jean Publicover PhD,?Jyotsna Gulati PhD,?Nestor Molfino MD,
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Type 2 (T2) immune–mediated epithelial-driven diseases are characterized by dysregulated immune responses at epithelial barrier surfaces. A key mediator of these diseases is thymic stromal l

应助信息

1小时前

jie81

bef25c9ddab311f187be208810ba6e4f.pdf 已采纳

1小时前

Book学术机器人

2026/11/7 22:01:16 未找到该文献，机器人已退出，请等待人工下载

2026/11/7 22:01:16 Book学术AI机器人收到请求，开始寻找文献

2026/11/7 22:01:16 已向机器人发送请求

1小时前

大三发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网聚氨酯声学复合材料研究进展